Drug Profile
Hetrombopag - Jiangsu Hengrui Medicine Co.
Alternative Names: Hengqu; Herombopag olamine; Hetrombopag olamine; Hytrapopapa ethanolamine; Hytrapopapamin; SHR 8735; SHR 8735 olamineLatest Information Update: 15 Dec 2023
Price :
$50
*
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Developer Atridia; Jiangsu Hengrui Medicine Co.
- Class Antianaemics; Antihaemorrhagics; Aza compounds; Carboxylic acids; Furans; Pyrazolones; Small molecules; Tetrahydronaphthalenes
- Mechanism of Action Thrombopoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Aplastic anaemia; Idiopathic thrombocytopenic purpura
- Phase III Thrombocytopenia
- Phase I Unspecified
Most Recent Events
- 02 Nov 2023 Jiangsu HengRui Medicine completes a phase I bioequivalence trial in Healthy volunteers in China (PO)(NCT05088655)
- 02 Oct 2023 Jiangsu Hengrui Medicine Co. plans a phase I trial (In volunteers) in October 2023 (PO) (NCT06062680)
- 28 Sep 2023 Jiangsu HengRui Medicine withdraws a phase III trial in Thrombocytopenia (Chemotherapy-Induced) (PO) due to sponsor's R & D strategy adjustment as of September 2023 (NCT05261646)